Chronic Itch

Chronic pruritus — itch persisting beyond six weeks — affects roughly one adult in seven at any time and a substantial majority of the very old, and by quality-of-life instruments it rivals chronic pain: sleep destroyed nightly, concentration eroded, mood measurably depressed, and the scratch-damage cycle adding wounds and infection to the original misery. Yet it occupies a fraction of pain's clinical attention, routinely dismissed as symptom rather than disease. Neuroscience has ended that excuse: itch runs on dedicated neural circuitry — specific fibres, spinal pathways and mediators (histamine only one among many; IL-31, IL-4/13, opioid-receptor imbalance and neural sensitisation carrying chronic itch) — which is why antihistamines fail most chronic itch, why scratching begets itching, and why the new biologics work.

The entire workup pivots on one observation: is there a primary rash? Itch with primary skin disease routes to the dermatoses — atopic dermatitis, psoriasis, urticaria, lichen planus, bullous pemphigoid in the elderly (its pre-blister phase is pure itch), and always, always scabies, the great impersonator whose missed diagnosis wastes months. Itch without primary rash (scratch marks do not count) mandates the systemic screen: kidney and liver function (uraemic and cholestatic itch), iron studies (deficiency itches), thyroid, glucose, and a blood count with the awareness that generalised itch can precede lymphoma — plus the drug list read honestly (opioids, some antihypertensives) and, in the itchy elderly, the commonest answer of all: the invisible dryness of ageing skin. Localised no-rash itch has its own neurological map — brachioradial pruritus of the forearms and notalgia paraesthetica of the mid-back are nerve-entrapment itches, treated as such.

Prurigo nodularis — the fortress endpoint of chronic itch, where years of scratching build intensely itchy nodules that perpetuate themselves — went from zero approved therapies to two in three years: dupilumab (IL-4/13 blockade, 2022, the first ever) and nemolizumab (anti-IL-31-receptor — the itch cytokine directly — 2024), each producing majority itch reduction in trials for a disease whose previous care was improvised immunosuppression. The ripple matters beyond PN: the same mechanisms serve atopic itch (dupilumab's home territory; JAK inhibitors adding rapid-onset oral and topical options), difelikefalin (a peripheral kappa-opioid agonist) earned approval for haemodialysis itch, and the pipeline treats itch as a target class rather than a nuisance. Chronic itch is becoming what chronic pain became decades ago: a field.

Beneath the biologics sits the layer that serves every itchy patient and cures the commonest cases outright. Dry-skin care: generous bland emollients applied to damp skin, cooler shorter showers, soap replaced with wash creams — this alone resolves much elderly itch. Behavioural circuit-breaking: nails short, cotton gloves at night, cooling (menthol creams, cold packs) as the scratch substitute, and habit-reversal techniques with genuine trial support — because scratch-damage is half the disease. Topical anchors: corticosteroids where inflammation exists, calcineurin inhibitors for delicate sites, capsaicin for localised neuropathic patterns. Systemic workhorses beyond antihistamines (which serve urticaria and little else): gabapentinoids for neuropathic and uraemic itch, certain antidepressants (mirtazapine at night, SSRIs in cholestatic itch) acting on itch circuitry rather than mood, and phototherapy as the broadly useful, underprescribed middle option.

Chronic itch runs a self-tightening triangle: itch wrecks sleep, sleep loss amplifies itch perception (measured, not metaphorical), and the exhaustion-plus-visible-scratching feeds anxiety and depression that lower the itch threshold further — nocturnal itch being the signature complaint because distraction disappears and skin warms. Effective care names the triangle: sedating-arm treatments timed at night, sleep hygiene treated as itch therapy, scratching-in-sleep managed mechanically (gloves, trimmed nails, cool bedroom), and mood screened and treated as a component of the itch rather than an embarrassing afterthought. Psychodermatology has trial-supported tools here (habit reversal, CBT variants); stigma is the main barrier to using them. The framing patients deserve: itch this persistent is a nervous-system condition with skin expression — treatable on both fronts, and blameworthy on neither.

Itch beyond six weeks earns a proper evaluation, not another antihistamine: with a rash — dermatology, and make sure scabies has genuinely been considered; without one — the systemic screen (kidney, liver, iron, thyroid, glucose, blood count) plus a hard look at the drug list, and specialist referral if clear. While seeking answers, run the foundations: emollients on damp skin, cool short washes, nails short, cooling instead of scratching, night-time management prioritised. For prurigo nodularis: approved therapy now exists — dupilumab and nemolizumab — and improvised steroid-and-suffer regimens are no longer the ceiling; ask. For the itchy elderly: assume dryness first, treat it seriously, and screen once. And for anyone told it is just itch: the circuitry, the trials and the approvals all say otherwise.